PMV director granted 42,000 stock options

PMV Pharmaceuticals, Inc. director Arnold J. Levine received a grant of stock options covering 42,000 shares of Common Stock at an exercise price of $1.1900 per share.

Rhea-AI Filing Summary

PMV Pharmaceuticals, Inc. director Arnold J. Levine received a grant of stock options covering 42,000 shares of Common Stock at an exercise price of $1.1900 per share. These options expire on June 4, 2036 and vest on the earlier of June 4, 2027 or the issuer's next annual meeting of stockholders, leaving him with 42,000 options following the grant.

Insider Trade Summary

Grant/Award: 42,000 shares

Grant/Award 1 txn

Insider LEVINE ARNOLD J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	42,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 42,000 contracts (Direct)

Footnotes (1)

1. F1. Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders.

Key Figures

Options granted: 42,000 options Exercise price: $1.1900 per share Underlying shares: 42,000 shares +3 more

6 metrics

Options granted 42,000 options Stock Option (right to buy) grant to director

Exercise price $1.1900 per share Exercise price of granted stock options

Underlying shares 42,000 shares Common Stock underlying the option grant

Options after grant 42,000 options Total options following transaction

Vesting date Earlier of June 4, 2027 or next annual meeting Vesting condition for the option grant

Expiration date June 4, 2036 Option expiration for the grant

Key Terms

Stock Option (right to buy), Common Stock, vest, annual meeting of stockholders, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vest financial

"Shares subject to the option vest on the earlier of (i) June 4, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

annual meeting of stockholders financial

"or (ii) the date of the Issuer's next annual meeting of stockholders."

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PMV Pharmaceuticals (PMVP) director Arnold J. Levine receive in this Form 4?

Arnold J. Levine received a grant of stock options covering 42,000 shares of PMV Pharmaceuticals Common Stock. The options are a compensation-related award, not an open-market purchase or sale, and give him the right to buy shares at a fixed exercise price.

What is the exercise price of Arnold J. Levine’s PMVP stock options?

The stock options granted to Arnold J. Levine have an exercise price of $1.1900 per share. This means he can buy PMV Pharmaceuticals Common Stock at $1.1900, regardless of future market price, once the options are vested and exercisable.

How many PMV Pharmaceuticals shares are covered by Arnold J. Levine’s options?

The option grant covers 42,000 underlying shares of PMV Pharmaceuticals Common Stock. Following this transaction, his total stock option holdings reported in this award amount to 42,000 options, each corresponding to one share of Common Stock upon exercise.

When do Arnold J. Levine’s PMVP stock options vest?

The options vest on the earlier of June 4, 2027 or the date of PMV Pharmaceuticals’ next annual meeting of stockholders. Vesting determines when he can begin exercising the options to purchase shares at the fixed $1.1900 exercise price.

When do Arnold J. Levine’s PMV Pharmaceuticals stock options expire?

The options expire on June 4, 2036. After this expiration date, Arnold J. Levine will no longer be able to exercise the options to buy PMV Pharmaceuticals Common Stock, even if they have vested and were previously exercisable.

Is Arnold J. Levine buying or selling PMVP shares in this transaction?

This transaction is a grant of stock options, classified as an acquisition under code A, rather than a market buy or sell. It reflects a compensation award giving him rights to purchase shares later, not an immediate share purchase or sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LEVINE ARNOLD J

(Last) (First) (Middle)

C/O PMV PHARMACEUTICALS, INC.

400 ALEXANDER PARK DRIVE, SUITE 301

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PMV Pharmaceuticals, Inc. [ PMVP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.19	06/04/2026		A		42,000		(1)	06/04/2036	Common Stock	42,000	$0	42,000	D

Explanation of Responses:

1. Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders.

	/s/ Robert Ticktin, by power of attorney	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)